In a notable departure from traditional regulatory practice, the US Food and Drug Administration has proactively added Janssen Pharmaceuticals’ combination therapy of teclistamab plus daratumumab, known as Tec-Dara, to its Commissioner’s National Priority Voucher (CNPV) pilot program. Rather than waiting for a formal request from the sponsor, FDA reached out directly after reviewing early clinical results that regulators described as highly promising.
The decision reflects FDA’s increasing willingness to take an active role in identifying potentially transformative therapies, particularly those addressing serious unmet medical needs in oncology.
What Prompted FDA’s Action
FDA announced on December 15 that it contacted Janssen after reviewing results from a Phase 3 clinical trial evaluating Tec-Dara in patients with relapsed or refractory multiple myeloma. Preliminary data were first released in late November and later published in a peer-reviewed medical journal in early December.
According to FDA, the trial demonstrated significant improvements in both progression-free survival and overall survival compared with standard of care in patients who had received one to three prior lines of therapy. The agency highlighted that approximately 80 percent of patients remained free from disease progression three years after treatment, outcomes that FDA characterized as clinically meaningful.
FDA leadership stated that internal experts reviewed the trial data shortly after it appeared in a major scientific conference program and moved quickly to engage the sponsor about inclusion in the CNPV pilot program.
Understanding the CNPV Pilot Program
The Commissioner’s National Priority Voucher pilot program was introduced in mid-2025 to accelerate the review of investigational drugs that address significant unmet needs or are considered critical from a public health or national interest perspective. Under the program, eligible therapies may receive dramatically shortened FDA review timelines, potentially reducing review from the traditional 10 to 12 months to as little as one to two months.
Tec-Dara is the sixteenth product to be included in the pilot program since its launch, highlighting FDA’s selective but expanding use of this expedited pathway.
Balancing Speed With Regulatory Rigor
While the proactive offer underscores FDA’s commitment to accelerating access to promising therapies, former FDA leadership has cautioned that early clinical results do not always reflect the final data submitted for regulatory review. Differences can emerge between conference presentations, journal publications, and formal regulatory submissions, particularly as additional analyses, manufacturing details, and labeling considerations are finalized.
These factors reinforce the importance of maintaining regulatory rigor even as review timelines are compressed.
Implications for Drug Developers
FDA’s decision to proactively offer a CNPV voucher signals a potential shift in how the agency identifies and engages with high-impact therapies. For sponsors, this approach underscores the value of generating compelling, high-quality clinical evidence early and ensuring readiness across regulatory, manufacturing, and labeling functions to support accelerated review pathways.
How EMMA International Supports Accelerated Regulatory Pathways
At EMMA International, we support pharmaceutical and biotechnology companies pursuing expedited FDA pathways, including priority review strategies, accelerated approvals, and emerging programs such as the CNPV pilot. Our teams help clients align clinical evidence, regulatory strategy, and operational readiness to navigate accelerated timelines without increasing regulatory risk.
For more information on how EMMA International can assist, visit www.emmainternational.com or contact us at (248) 987-4497 or info@emmainternational.com.
Reference:
U.S. Food and Drug Administration. FDA announcement on inclusion of Tec-Dara in the Commissioner’s National Priority Voucher pilot program. December 2025.
New England Journal of Medicine. Phase 3 trial results for teclistamab plus daratumumab in relapsed or refractory multiple myeloma. December 2025.
Regulatory Affairs Professionals Society. FDA proactively offers CNPV voucher for Tec-Dara. December 2025.
